Covidien

With the opening of its new $45M facility Covidien’s investment in China is significant and a sure sign that the healthcare giant sees the Far East as the medtech powerhouse in years to come.

Covidien has announced FDA 510(k) clearance to market its Covidien Nellcor™ Bedside SpO2 Patient Monitoring System.

There’s no stopping Covidien’ s neurovascular clot retrieval device, which the company has announced can now add Brazil to Europe and USA as territories wher eit is approved for sale.

9 patient deaths are reportedly linked with catheter entrapment when delivering Covidien subsidiary ev3’sOnyx injectable embolic material into the brain. FDA has seen fit to warn users of the potential for this to occur.

Covidien has been on the unpleasant end of FDA’s big stick, the agency having written to the company about a raft of areas in which it has found the handling of the Duet TRS stapler recall to be inadequate.

Covidien’s acquisition of Oridion Systems Ltd. is complete, expanding the medtech giant’s portfolio of key monitoring technology to include the Israeli company’s capability in airway management.

Covidien’s V-Loc™ knotless suture has now been combined with its endoscopic suturing devices with claimed significant time saving for surgeons.

Covidien is announcing the global launch of its Nellcor SpO2 module designed for use on Philips patient monitoring platforms.

Covidien says its new Radial Reload allows surgeons to cut and securely staple colon tissue up to 2 cm deeper into the pelvis than the Ethicon Contour® Curved Cutter Stapler.

NICE, the healthcare guidance body, has today issued guidance supporting the use of Covidien’s Pipeline® device for the treatment of complex brain aneurysms.

Covidien’s quietly recalling its Roticulators for packaging concerns, but seems to be doing so by stealth rather than adopting the slightly more communicative route one might expect to see.

Covidien has unveiled its new range add HALO 90 ULTRA for ablative treatment of large Barrett’s Oesophagus lesions. The device, which comes from the stable of recently acquired Barrx Medical, is double the length of its HALO 90 brother and as such can reduce ablation treatment time and in so doing shorten the procedure.

Covidien told us in March it was to acquire Israeli company superDimension. The deal is now done in a transaction worth $300M plus earnouts.

Covidien and GE Healthcare will both benefit from their newly formalised alliance, which looks like another example of a device market which is employing what we could call pragmatic synergies to future proof itself.

Not many weeks go by without news of a Covidien acquisition, so its not too surprising when the tech titan takes a shine to a company who’s product can help place its hernia meshes in a speedy and effective fashion.

Covidien looks to be pressing all the right buttons as its year-on-year quarterly picture suggests sales are increasing while margins are also being driven up.